Asclepius: Single topic issues

Toxicology of Polonium

Asclepius — Wed, 29 Jul 2026 12:38:22 GMT

On 1 November 2006, a 43-year-old man walked into a London hospital with abdominal pain, diarrhoea, and vomiting. He was treated for gastroenteritis. Three weeks later he was dead, and Scotland Yard was investigating a murder committed with a substance so rare in human poisoning that his clinicians had never seen a case. That man was Alexander Litvinenko, and the poison was polonium-210 — an element that kills through physics.

Most poisons work by interfering with a biochemical pathway: blocking an enzyme, jamming a receptor, uncoupling a membrane gradient. Polonium-210’s lethality comes almost entirely from what happens inside the nucleus of the atom, not the outer electron shell that determines ordinary chemical reactivity. To understand this, we need to set toxicology aside for a moment and look more closely at nuclear physics.

Polonium-210 is unstable. It decays by emitting an alpha particle - a helium nucleus, two protons and two neutrons bound together - together with an occasional low-yield gamma photon. The half-life is 138 days, and it decays to stable lead-206.

Because it is relatively large, slow (compared to other radiation), and carries a double positive charge, an alpha particle interacts strongly with anything it hits, transfering nearly all its energy within a few tens of micrometres. That transfer is described by a value called linear energy transfer, or LET - essentially, how much energy a particle deposits per unit distance travelled. A typical alpha particle from an emitter like polonium has an LET roughly 400 times higher than a beta particle (electron) of comparable energy.

High LET translates directly into biological damage. Sparse, low-LET radiation such as gamma rays or beta particles tends to produce isolated single-strand DNA breaks that a cell can usually repair. Dense, high-LET alpha radiation instead causes clusters of double-strand breaks packed close together, overwhelming repair processes and producing the kind of catastrophic, irreparable genomic damage that kills the cell or triggers malignant transformation. This is why radiation protection standards apply a weighting factor of roughly 20 to alpha radiation compared with 1 for gamma, beta, or X-rays; gray1 for gray of absorbed physical dose, alpha radiation is considered to be roughly twenty times more biologically damaging.

Alpha emitters are at the same time the least dangerous and the most dangerous form of ionising radiation, depending entirely on where they are. Outside the body, an alpha particle can’t even cross the dead outer layer of skin, a sheet of paper stops it completely. That lack of penetration is why polonium-210 is legally and commercially used, in tiny sealed quantities, as an anti-static device in industrial processes and film manufacturing, and why it triggers no alarm on a standard security scanner.

However, swallow, inhale, or otherwise internalise polonium 210, every particle now discharges its energy directly into living tissue, at a range too short to spread the damage out, with nothing between the decay and your DNA.

Once absorbed - via ingestion, inhalation, or a wound - polonium-210 concentrates first in red blood cells before redistributing over subsequent days to the liver, kidneys, spleen, bone marrow, gastrointestinal tract, and gonads. It is cleared slowly, through urine, bile, sweat and possibly breath, and is also deposited in hair, and has a biological half-life in the body of roughly 30 to 50 days - long enough, at a sufficient dose, to deliver a fatal cumulative radiation exposure over just a few days to weeks even though the isotope itself is being partly excreted the whole time.

The clinical picture reflects tissue distribution. Cells that divide rapidly - bone marrow, gut epithelium, hair follicles - are the most radiosensitive, so the syndrome that emerges is a fairly classic, if unusually severe and rapid, acute radiation syndrome:

Prodromal phase (hours to ~2 days): nausea, vomiting, anorexia, sometimes abdominal pain that can be mistaken for an acute abdomen or simple gastroenteritis.
Two days to ~2 weeks: progressive bone marrow suppression with falling platelets and neutrophils, along with mucositis and the beginnings of alopecia.
After two weeks: multi-organ deterioration as marrow failure, gastrointestinal breakdown, and direct organ radiotoxicity compound each other, frequently progressing to circulatory collapse and death.

Early symptoms are indistinguishable from a wide range of chemical toxins and from ordinary infective gastroenteritis, so without a high index of suspicion the diagnosis is easy to miss. Further, a standard Geiger counter run over the patient’s body will typically find nothing, because the alpha particles the polonimu emits can’t escape the tissue they’re embedded in to reach a detector outside the skin.

In the Litvinenko case, thallium poisoning was seriously entertained and only ruled out when blood thallium levels came back below toxic thresholds. The diagnosis was ultimately made by gamma-ray spectroscopy of a urine sample, picking up the incidental 803 keV gamma photon that accompanies a fraction of polonium-210 decays. The alpha decay does the damageg, but it is the gamma emission that gives the poison away analytically.

Whole-body counting and 24-hour urine or faecal radioactivity assays are the mainstay of confirming internal contamination once it’s suspected, and dose reconstruction can be performed retrospectively from measured tissue and excretion levels.

The practical lesson for any clinician: an unexplained gastrointestinal prodrome followed by progressive bone marrow failure and alopecia over the following one to three weeks should prompt consideration of radionuclide poisoning, however implausible it initially seems, because the initial presentation gives almost no other clue.

There is no way to reverse alpha-induced DNA damage once it has occurred; deposited energy has already done what it’s going to do at the moment of decay. Management is therefore aimed at reducing further internal redistribution and retention, alongside supportive care for the resulting marrow failure and organ dysfunction.

Dimercaprol (British Anti-Lewisite), with penicillamine as an alternative, is the chelating agent currently recommended for polonium-210 poisoning, on the basis of both limited clinical experience and animal data; other chelating agents have shown promise experimentally but lack the same evidence base.

Beyond chelation, treatment is essentially the ICU management of acute radiation syndrome - transfusion support, infection prophylaxis in the face of neutropoenia, and organ support as multi-organ failure develops. The outcome is ultimately decided by the size of the internalised dose rather than by anything the treating team can do to intervene in the underlying mechanism.

Polonium-210 is a reminder that poisoning doesn’t always involve molecules binding receptors. Sometimes the poison is a physical process - energy deposited at a very short distance, from a source inside the body - and the entire clinical and diagnostic picture, from the unremarkable prodrome to the false-negative Geiger counter, follows directly from the physics of polonium decay, and the penetration and energy transfer of alpha particles.

---

This piece is intended as a clinical and physiological review, not a comprehensive toxicology reference. Anyone managing a suspected case should consult national radiation protection and public health authorities immediately - in the UK, that means the UK Health Security Agency’s radiation, chemical and environmental hazards service.

A Self-Inflicted Wound: How DOGE Dismantled America’s Public Health Infrastructure — and Who Is Paying the Price

Asclepius — Fri, 26 Jun 2026 12:12:36 GMT

Photo by My Profit Tutor on Unsplash

Five Alerts, One City

As a million international visitors prepare to descend on New York City for the 2026 FIFA World Cup, the city’s public health authorities are managing five concurrent Infectious threats: the ongoing hantavirus quarantine of state residents; an active measles outbreak; an Ebola preparedness posture following the WHO’s declaration of a Public Health Emergency of International Concern for the Bundibugyo strain; a new COVID-19 sub-variant; and West Nile virus. Five separate pathogen threats and a federal public health infrastructure that has been systematically stripped of a quarter of its workforce, its institutional memory, and much of its moral authority to lead.

How the United States arrived at this moment is a story of choices: about what to cut and whose lives to treat as expendable.

The CDC: A Warning System Deliberately Degraded

In February 2025, the Trump administration’s Department of Government Efficiency (DOGE) began its assault on the Centers for Disease Control and Prevention. Approximately 1,270 staff — close to 10% of the agency’s workforce — were dismissed in the initial wave. Among those let go were fellows from the Laboratory Leadership Service, the specialist corps responsible for training public health laboratory leaders and supporting outbreak response. The Epidemic Intelligence Service — the CDC’s elite “disease detective” programme, whose officers are deployed to investigate outbreaks across the US and globally — was initially threatened with the loss of its entire first-year cohort, though those officers were ultimately spared after significant public protest.

Other fellowships were not spared, and the pipeline they represented — the next generation of CDC leadership — was severed. “Even if EIS was spared, there are multiple other fellowships that were not,” one senior CDC official told reporters. “We’re being cut off at the knees. It is going to cripple public health for decades.”

The cuts did not stop there. Since January 2025, the CDC has lost close to 3,000 employees in total — nearly a quarter of its entire workforce — through layoffs, forced retirements, and resignations triggered by the chaos of political interference and leadership instability. In August 2025, HHS Secretary Robert F. Kennedy Jr. fired CDC Director Susan Monarez after she refused to accept political interference with the agency’s scientific mission, prompting multiple senior leaders to resign in protest. The agency has now operated without Senate-confirmed leadership for almost the entire period of the measles crisis. A survey of 433 current and 191 former CDC staff conducted between February and April 2026 documented the effects: communication freezes, scientific interference, and an institution whose systems and institutional memory have been hollowed out even as its remaining staff try to hold the line.

The former CDC Chief Operating Officer Robin Bailey, speaking publicly in June 2026, was measured but unambiguous: “We lost a lot of talent. Many of the things that we put in place — I’m not sure that they’re operating in the same way.” He had spent years building the operational infrastructure to deal with multi-pathogen crises like the CDC was now facing — the hantavirus cluster, the Ebola outbreak, the measles surge. The reforms have been put in place but the workforce responsible has been dismantled.

The Measles Catastrophe: Policy, Misinformation, and Preventable Deaths

Robert F. Kennedy Jr., confirmed as HHS Secretary in February 2025, is the founder of Children’s Health Defense, one of the most influential anti-vaccine organisations in the United States. His record of spreading vaccine misinformation stretches back decades: false claims linking the MMR vaccine to autism, assertions that “there is no vaccine that is safe and effective,” and sustained campaigns to erode public confidence in childhood immunisation schedules. His appointment placed the person most responsible for the ideological conditions enabling the measles resurgence in direct control of the agencies charged with stopping it. This seems to be a pattern.

The results were immediate. On 26 February 2025 — the day after Kennedy was confirmed — the first measles death in the United States in more than a decade was reported in Texas: an unvaccinated eight-year-old girl. Kennedy’s response was to tell the White House Cabinet meeting that measles outbreaks were “not unusual.” A fortnight later, a second child died. Kennedy told Fox News that the MMR vaccine “kills people every year,” causes “the same symptoms as measles,” and “does not appear to provide maternal immunity.” Texas state health officials confirmed both deaths were caused by measles, Kennedy falsely implied otherwise.

By March 2026, more than 3,800 measles cases had been reported across US states since January 2025 — the largest sustained outbreak in a generation. The Americas as a whole recorded over 21,000 confirmed cases in the first five months of 2026, a 234% increase on the same period in 2025. In January 2026, the CDC reduced its childhood immunisation schedule from 17 recommended vaccines to 11, removing six from universal recommendation at the direction of President Trump and Kennedy. Legal experts questioned the administration’s authority to implement this change without Senate approval. Public health experts warned it would further erode vaccine uptake at the worst possible moment.

The United States has held measles elimination status since 2000 (no sustained domestic transmission for twelve consecutive months). PAHO’s Regional Monitoring Commission has now invited both the US and Mexico to review their elimination status. If the US loses it, the achievement of a generation of public health work will have been undone in under two years.

USAID and the Global Retreat

On 20 January 2025, President Trump signed an executive order initiating the United States’ withdrawal from the WHO and imposing a 90-day freeze on all USAID activities globally. Within weeks, DOGE had effectively dismantled USAID as an operational agency, absorbing its remnants into the State Department. By March 2025, 83% of USAID’s approximately 6,200 global programmes had been permanently terminated.

HIV clinics across sub-Saharan Africa received immediate “work stop” letters and closed within days, cutting approximately 20 million people supported by PEPFAR off from antiretroviral medicine. Measles mass vaccination campaigns, running in regions already experiencing surging outbreaks, were halted without notice. Malaria vaccine rollouts were disrupted. Nutrition programmes ended. The WHO, which had received approximately 18% of its funding from the United States, was forced to begin cutting staff and programmes to close a 25% budget shortfall that it has not yet recovered.

Conservative academic estimates calculated that USAID programme cancellations could contribute to 500,000 to 700,000 additional deaths annually. A year on from the cuts, a whistle-blower writing in the Boston Globe placed the confirmed toll at 750,000 additional deaths in 2025, and noted that for the first time in a generation, more children died in a single year than in the year before. The same article observed that the Bundibugyo Ebola outbreak, now a PHEIC (Public Health Emergency of International Concern), took far longer to identify than previous outbreaks because the US retreat from the global health stage had removed critical early warning and surveillance infrastructure from the region where the outbreak began.

The US withdrawal also directly undermined the outbreak response tools available for Bundibugyo. DOGE’s cuts included the NIH Vaccine Research Centre, the institution responsible for discovering the Ebola vaccines now deployed against the more common Zaire strain. Bundibugyo has no approved vaccine or treatment. The US was the world’s largest source of funding for the global health architecture that might have accelerated countermeasure development. That architecture has been dismantled.

Photo by Agustin Fernandez on Unsplash

The World Cup as Diagnostic

New York’s five concurrent public health alerts, viewed in context, are diagnostic: an example of what happens when you systematically degrade public health surveillance, outbreak response capacity, vaccine confidence, and global early-warning systems simultaneously, and then host a mass gathering of one million international visitors.

The pathogens themselves (measles, hantavirus, Ebola, West Nile, COVID) are not novel. What is new is the environment in which they are now operating. Measles has an R0 of 12–18; in a population where vaccination coverage has been eroded by eighteen months of mixed and misleading messaging from the country’s most senior health official, a mass gathering is not a contained risk. Hantavirus is normally a sporadic zoonosis; the quarantine management of the cruise ship cluster has been competent, but the outbreak response capacity that would normally back this up has been thinned. Ebola preparedness is only as reliable as the surveillance systems and those systems have been cut.

Public health infrastructure is not visible until it fails. It does not appear on a balance sheet as an asset. Its value is measured in the crises that do not happen, the outbreaks that are caught early, the deaths that are prevented rather than mourned. DOGE’s idiotic logic was that you could measure government efficiency by counting headcount and cutting it. The logic of infectious disease is different: the cost of dismantling a warning system is paid later, by people who had no say in the decision.

In the US, the measles outbreak has fallen hardest on unvaccinated children in low-income and marginalised communities where vaccine access was already uneven and misinformation spread readily. Globally, the populations most affected by USAID terminations were those already carrying the greatest burden of preventable disease: sub-Saharan Africa, South and Southeast Asia, conflict-affected, and poor, regions where US-funded health infrastructure was often the only infrastructure available.

The fiscal justification for DOGE’s cuts rested upon treating global health spending as discretionary foreign largesse. What it actually was, and what the past eighteen months have demonstrated, is a form of collective insurance: investment in outbreak detection and containment in regions far from the US border that directly protects the US from the pathogens those regions would otherwise export. Cutting it did not eliminate the risk. It transferred the cost — from the federal balance sheet to the children in Texas, patients in African HIV clinics, and a global surveillance system now operating with a structural gap where the world’s largest contributor used to be.

The World Cup will pass. The five alerts will be managed, one way or another. But the institutional damage to the CDC, the erasure of a generation’s worth of global health infrastructure, and the active promotion of vaccine misinformation from within the US government will outlast any tournament. The question for the next administration is how long it takes to rebuild what has been destroyed by the Trump administration, and how many preventable deaths will occur between now and the return of a sensible health policy.

Diplopia After COVID-19: A Cautious Neuro-Ophthalmic Perspective

Asclepius — Thu, 26 Feb 2026 14:11:02 GMT

Photo by Ion Fet on Unsplash

As understanding of post-COVID syndromes matures, clinicians increasingly encounter neurological symptoms extending beyond fatigue and cognitive dysfunction. Visual complaints are common, but most are non-specific. Diplopia is less frequent, yet it warrants careful attention because it usually indicates disturbance of ocular alignment or ocular motor control rather than primary ocular surface disease.

The published evidence to date supports a cautious position: ocular motor palsies and diplopia have been reported following SARS-CoV-2 infection, chiefly in acute and subacute settings, and their prevalence and natural history within clearly defined Long Covid cohorts remain incompletely characterised. Early in the pandemic, Neurology reports described COVID-19 presenting with ophthalmoparesis attributable to cranial nerve palsy. Subsequent literature has continued to document oculomotor, trochlear, and abducens nerve palsies temporally associated with COVID-19 infection.

Beyond discrete cranial nerve palsies, a separate strand of evidence concerns oculomotor control in post-COVID condition (PCC). Objective eye-tracking studies in PCC, particularly among individuals with cognitive complaints, have reported alterations across saccades, pursuit, fixation, vergence, and pupillary parameters. Other cohorts have reported vision-related symptoms and measurable oculomotor findings in non-hospitalised post-COVID populations. These studies support the broader proposition that ocular motor function may be affected in some PCC patients. However, it remains premature to claim that specific syndromes such as convergence insufficiency are common without stronger prevalence data.

A small but important differential is myasthenia gravis (MG). New-onset MG has been reported after SARS-CoV-2 infection, sometimes beginning with oculo-bulbar symptoms including diplopia and ptosis. While myasthenia gravis is unlikely to explain most post-COVID visual complaints, its consequences are significant enough that fluctuating diplopia or fatigable ptosis should trigger appropriate evaluation and referral.

For generalists, the practical message remains one of measured vigilance. New-onset diplopia requires structured assessment and urgent triage where red flags are present. Where investigations are unrevealing and symptoms are stable, a post-infectious mechanism may be considered---but only after exclusion of time-critical pathology.

In summary, the evidence supports that diplopia and ocular motor dysfunction can occur after SARS-CoV-2 infection, and objective studies suggest oculomotor control changes in some PCC patients. What remains uncertain is how often diplopia forms part of Long Covid, which patients are at risk, and which interventions best help. Until better cohort data emerge, clinical curiosity should be paired with careful follow-up.

Long Covid and diplopia — key clinical points

The Renin-Angiotensin-Aldosterone System - An Overview.

Asclepius — Sun, 01 Feb 2026 08:16:04 GMT

Photo by Joshua Chehov on Unsplash

Summary.

The RAAS is a critical hormonal cascade that helps maintain arterial blood pressure, extracellular fluid volume, and electrolyte balance. It co-ordinates renal, vascular, and adrenal functions and interfaces with the sympathetic nervous system, vasopressin release, natriuretic peptides and local tissue systems (notably in the heart, kidney, and brain). It is a finely tuned, multi-organ system that maintains cardiovascular and fluid homeostasis.

Dysregulation contributes to hypertension, heart failure, kidney disease, and inflammatory pathologies. The RAAS is a critical hormonal cascade that helps maintain arterial blood pressure, intravascular volume, and electrolyte balance. It co-ordinates renal, vascular, and adrenal functions and interfaces with the sympathetic nervous system, vasopressin release, and local tissue systems (notably in the heart, kidney, and brain).

Modern therapeutics target this system at multiple points — renin, ACE, AT₁ receptors, and aldosterone — to modulate its activity and prevent end-organ damage.

Pathway.

Renin is synthesised and stored in juxtaglomerular (JG) cells of the kidney afferent arteriole, and is released into the blood in response to reduced renal perfusion pressure (detected by juxtaglomerular baroreceptors) and to reduced sodium chloride delivery to the macula densa.

It is also released in response to sympathetic activation via β₁-adrenoceptors at the juxtaglomerular cells.

Renin, an aspartyl protease, cleaves angiotensinogen in plasma to the decapeptide angiotensin I (Ang I).

Angiotensinogen, itself, is a glycoprotein produced mainly by the liver. Its production is increased by oestrogen, corticosteroids, thyroid hormone, and inflammation (IL-6–mediated).

Circulating angiotensin I is inactive but is converted to the active angiotensin II by Angiotensin-Converting Enzyme (ACE) on the vascular endothelial cells - particularly in the pulmonary and renal circulations. Angiotensin-Converting Enzyme removes two amino acids from angiotensin I to form angiotensin II (Ang II). It also degrades bradykinin, a vasodilator peptide, adding to the vasoconstrictive effect .

Angiotensin II acts mainly on the angiotensin II receptors AT₁ and AT₂ (both G protein-coupled receptors).

AT₁R: Mediates vasoconstriction, aldosterone release, sympathetic activation, sodium retention, and cellular growth.

AT₂R: Counter-regulatory — promotes vasodilation, anti-proliferation, apoptosis, and NO release. Although angiotensin II binds both AT₁ and AT₂ receptors, many of the vasodilatory and anti-fibrotic effects classically attributed to AT₂ activation are mediated in parallel by the angiotensin-(1–7)/Mas receptor axis.

Aldosterone is synthesised in the zona glomerulosa of the adrenal cortex. It is released following Ang II stimulation, directly in hyperkalaemia and, to a lesser extent, in response to ACTH.

It binds mineralocorticoid receptors in the distal nephron (principal cells) to:

↑ Na⁺ reabsorption via the epithelial sodium channels (ENaC) channels.

↑ K⁺ secretion via the renal outer medullary potassium (ROMK) channels.

↑ water reabsorption (secondary to sodium retention).

Aldosterone activity results in expanded extracellular volume and elevated blood pressure.

The effects of RAAS activity are counterbalanced by ACE2 which converts Ang II to Ang (1–7). This acts via Mas receptors producing vasodilation, anti-fibrosis, and anti-inflammatory effects.

Natriuretic peptides (ANP, BNP) also oppose RAAS activity by promoting loss of sodium in the urine, vasodilation, and suppression of renin/aldosterone.

Physiological Effects.

Cardiovascular.

Angiotensin II acts directly upon AT₁ receptors in vascular smooth muscle producing vasospasm, so increasing systemic vascular resistance (SVR). If the cardiac output remains constant, this action will increase the blood pressure.

Direct cardiac effects include positive inotropy and myocardial hypertrophy. Chronic stimulation can lead to myocardial fibrosis.

Renal.

RAAS activity promotes efferent arteriolar constriction which maintains glomerular filtration pressure during hypotension.

At the renal tubules, aldosterone increases Na⁺ reabsorption and K⁺ secretion in the principal cells of the distal tubule and collecting duct via its effect upon the epithelial sodium channels (ENaC) and the renal outer medullary potassium channels (ROMK channels).

Neurohormonal.

The RAAS can stimulate thirst through its effects upon the hypothalamus, and increase ADH (vasopressin) release which leads to water retention.

There is also sympathetic activation via brainstem nuclei, with consequent adrenergic effects upon the heart and circulation.

Cellular Mechanisms.

AT₁ Receptor: A G-protein–coupled receptor (GPCR) activating phospholipase C leads to IP₃ + DAG, ↑ intracellular Ca²⁺ and, consequently, vasoconstriction, aldosterone synthesis, and cellular growth.
Aldosterone mechanism: Nuclear receptor binding leads to increased transcription of ENaC and Na⁺/K⁺-ATPase subunits so facilitating increased Na⁺ re-uptake.

Clinical Relevance.

In heart failure, chronic RAAS activation leads to vasoconstriction, sodium retention and cardiac remodelling. ACE inhibitors, ARBs, MRAs (spironolactone) can be beneficial.

Hypertension is associated with over-activity of the angiotensin II/aldosterone axis. Appropriate therapeutic options include ACE inhibitors, angiotensin receptor blockers and renin inhibitors.

Glomerular hypertension and fibrosis from persistent from persistent angiotensin II stimulus is a feature of chronic kidney disease (CKD). RAAS blockade can slow CKD progression.

In COVID-19, use of ACE2 receptor by the coronavirus disrupts balance between angiotensin II and angiotensin (1-7) and AT₁R and MasR signalling - a possible link to endothelial injury and cytokine storm; also to potential therapeutic options.

Fortified Wines - Their Effects Upon Health.

Asclepius — Thu, 04 Dec 2025 16:15:19 GMT

Photo by Bruno Martins on Unsplash

Phantosmia

Asclepius — Mon, 24 Nov 2025 13:51:30 GMT

Photo by Battlecreek Coffee Roasters on Unsplash